AbCellera Biologics shares surged 33.19% to a 52-week high of $11.32 after positive Phase 2 results for ABCL635 showed the experimental menopause treatment reduced hot flash frequency by 83%. The move extended an earlier rise that had lifted the stock 1.69% to $9.92 near a then-52-week high of $10.29 when the company also launched a $200 million underwritten public offering of common shares and pre-funded warrants. AbCellera said the financing will support research, development and clinical advancement across its internal pipeline, including ABCL635, as well as working capital and general corporate purposes. Analyst sentiment remained constructive, with a Buy consensus, an average price forecast of $14.60, and recent target increases from Truist Securities, Stifel and Cantor Fitzgerald.